Quest Diagnostics Incorporated (NYSE:DGX)‘s stock had its “hold” rating reiterated by KeyCorp in a research note issued to investors on Friday.
DGX has been the topic of several other research reports. ValuEngine raised shares of Quest Diagnostics from a “hold” rating to a “buy” rating in a research report on Friday, September 1st. Wells Fargo & Company dropped their target price on shares of Quest Diagnostics from $88.00 to $86.00 and set a “market perform” rating on the stock in a research report on Friday, October 20th. Zacks Investment Research cut shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a research report on Thursday, August 3rd. Goldman Sachs Group, Inc. (The) cut shares of Quest Diagnostics from a “conviction-buy” rating to a “buy” rating and dropped their target price for the stock from $121.00 to $113.00 in a research report on Tuesday, October 10th. Finally, BidaskClub cut shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a research report on Monday, July 24th. Two analysts have rated the stock with a sell rating, fourteen have issued a hold rating and seven have issued a buy rating to the company’s stock. Quest Diagnostics currently has an average rating of “Hold” and an average price target of $106.18.
Quest Diagnostics (DGX) traded up 0.93% during mid-day trading on Friday, reaching $95.68. The company’s stock had a trading volume of 887,486 shares. The firm has a 50 day moving average price of $96.64 and a 200 day moving average price of $104.44. Quest Diagnostics has a 52-week low of $79.28 and a 52-week high of $112.97. The company has a market cap of $13.05 billion, a price-to-earnings ratio of 19.28 and a beta of 0.65.
Quest Diagnostics (NYSE:DGX) last released its quarterly earnings results on Thursday, October 19th. The medical research company reported $1.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.35 by $0.04. The business had revenue of $1.93 billion during the quarter, compared to the consensus estimate of $1.92 billion. Quest Diagnostics had a return on equity of 15.53% and a net margin of 8.82%. The company’s quarterly revenue was up 2.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.37 EPS. Equities research analysts anticipate that Quest Diagnostics will post $5.64 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: This piece was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2017/10/29/keycorp-reiterates-hold-rating-for-quest-diagnostics-incorporated-dgx.html.
In other Quest Diagnostics news, Director Jeffrey M. Leiden sold 296 shares of the business’s stock in a transaction on Friday, August 4th. The shares were sold at an average price of $106.66, for a total transaction of $31,571.36. Following the sale, the director now owns 6,000 shares of the company’s stock, valued at approximately $639,960. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Chairman Stephen H. Rusckowski sold 59,235 shares of the business’s stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $108.16, for a total transaction of $6,406,857.60. Following the sale, the chairman now directly owns 220,049 shares in the company, valued at approximately $23,800,499.84. The disclosure for this sale can be found here. Insiders have sold a total of 160,692 shares of company stock worth $17,375,423 in the last three months. Insiders own 1.75% of the company’s stock.
A number of hedge funds have recently modified their holdings of DGX. FMR LLC raised its holdings in Quest Diagnostics by 2.4% during the 1st quarter. FMR LLC now owns 759,611 shares of the medical research company’s stock valued at $74,586,000 after acquiring an additional 17,794 shares during the period. Teachers Advisors LLC raised its holdings in Quest Diagnostics by 23.6% during the 1st quarter. Teachers Advisors LLC now owns 219,065 shares of the medical research company’s stock valued at $21,510,000 after acquiring an additional 41,822 shares during the period. Thrivent Financial For Lutherans raised its holdings in Quest Diagnostics by 4.5% during the 1st quarter. Thrivent Financial For Lutherans now owns 5,100 shares of the medical research company’s stock valued at $501,000 after acquiring an additional 220 shares during the period. Morgan Stanley raised its holdings in Quest Diagnostics by 36.1% during the 1st quarter. Morgan Stanley now owns 404,522 shares of the medical research company’s stock valued at $39,720,000 after acquiring an additional 107,330 shares during the period. Finally, Oppenheimer Asset Management Inc. bought a new stake in Quest Diagnostics during the 1st quarter valued at $741,000. 87.08% of the stock is currently owned by institutional investors and hedge funds.
About Quest Diagnostics
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).
Receive News & Ratings for Quest Diagnostics Incorporated Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Quest Diagnostics Incorporated and related companies with MarketBeat.com’s FREE daily email newsletter.